TN 38 (09-20)

DI 23022.600 Angelman Syndrome

COMPASSIONATE ALLOWANCES INFORMATION

ANGELMAN SYNDROME

ALTERNATE NAMES

AS

DESCRIPTION

Angelman Syndrome (AS) is a rare genetic neurological disorder that involves a deletion of chromosome 15q and mutation of the UBE3A gene. It is characterized by developmental delay, intellectual disability, and severe speech impairment with a limited vocabulary (usually consisting of less than 10 words). Some children with this disorder experience recurrent seizures varying from major motor to a sudden brief lapse in muscle tone (akinetic).

Children with AS are described as generally happy with an excitable demeanor and frequent smiling, laughter, and hand-flapping movements. Hyperactivity and a short attention span are common. Developmental delays become noticeable by age 6 to 12 months, and seizures generally begin between 2 and 3 years of age. Many children with AS also have difficulty sleeping.

DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM/ICD-10-CM CODING

Diagnostic testing: The diagnosis of AS is established by a combination of clinical features and molecular genetic testing and/or fluorescent in situ hybridization (FISH) analysis.

Physical findings: Physical symptoms include:

  • Small head size (microcephaly);

  • Hypotonia (reduced muscle strength);

  • Scoliosis (curved or crooked spine);

  • Ataxia (difficulties with coordination, balance and spasticity); and

  • Seizures.

ICD-9: 759.89

ICD-10: Q93.51

PROGRESSION

People with AS may survive into adulthood but continue to have severe cognitive and communication impairments. The intensity and frequency of seizures tends to subside with age.

TREATMENT

There is currently no cure for this disorder. Management of AS includes treatment of seizures, physical and occupational therapies to improve adaptive functioning, and speech therapy with a focus on non-verbal methods of communication. School age children require individualized and flexible instructional curricula.

SUGGESTED PROGRAMMATIC ASSESSMENT*

Suggested MER for Evaluation:

  • Clinical examination that describes diagnostic features of the impairment and laboratory findings are needed to confirm the diagnosis.

  • Developmental assessment or psychological testing to address allegations of mental impairment may be warranted.

Suggested Listings for Evaluation:
DETERMINATION LISTING REMARKS
Meets 12.05

AS involves multiple body systems. A description of clinical and laboratory findings will be needed to adjudicate these cases.

110.08 B

AS involves multiple body systems. A description of clinical and laboratory findings will be needed to adjudicate these cases.

112.05

AS involves multiple body systems. A description of clinical and laboratory findings will be needed to adjudicate these cases.
Equals
* Adjudicators may, at their discretion, use the Medical Evidence of Record or the listings suggested to evaluate the claim. However, the decision to allow or deny the claim rests with the adjudicator.

 

 


To Link to this section - Use this URL:
http://policy.ssa.gov/poms.nsf/lnx/0423022600
DI 23022.600 - Angelman Syndrome - 09/16/2020
Batch run: 07/21/2021
Rev:09/16/2020